EICHORCondition: Leukemia, Myeloid, Acute · AML Stage, Adult · Sponsor: The First Affiliated Hospital of Xiamen University
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
This description comes directly from the study's public registry record.
Bing Xu, M.D. · +865922137255 · xubingzhangjian@126.com
Zhifeng Li · +8613606901162 · lzf_xm@163.com
Always discuss trial participation with your own doctor first.
| Bing Xu | Xiamen, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05603884